# Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers

> **NCT04471519** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bharat Biotech International Limited** · enrollment: 755 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** BBV152A - Phase I
- **BIOLOGICAL:** BBV152B - Phase I
- **BIOLOGICAL:** BBV152C - Phase I
- **BIOLOGICAL:** Placebo - Phase I
- **BIOLOGICAL:** BBV152A - Phase II
- **BIOLOGICAL:** BBV152B - Phase II

## Key facts

- **NCT ID:** NCT04471519
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2020-07-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 755 (ACTUAL)
- **Last updated:** 2022-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471519, "Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04471519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*